The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

The president said he would first install a “small tariff” on pharmaceutical goods before ratcheting up the rate over the ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...

Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

Extend transfection complex formation time by up to 3 hours, reduce complex volume by >50% and maintain high titers and full ...